Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Moderna's profit margin for the twelve months ending Jun 30, 2026 was -141.4%. For fiscal 2025 it was -145.2%, against -110.0% the year before. The highest annual figure on record is 66.1% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -145.2% | −35.1 |
| FY2024 | Dec 31, 2024 | -110.0% | −41.2 |
| FY2023 | Dec 31, 2023 | -68.8% | −112.2 |
| FY2022 | Dec 31, 2022 | 43.4% | −22.7 |
| FY2021 | Dec 31, 2021 | 66.1% | +159.1 |
| FY2020 | Dec 31, 2020 | -93.0% | +763.6 |
| FY2019 | Dec 31, 2019 | -856.7% | −571.8 |
| FY2018 | Dec 31, 2018 | -284.8% | −160.5 |
| FY2017 | Dec 31, 2017 | -124.3% | +75.1 |
| FY2016 | Dec 31, 2016 | -199.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -539.3% | +41.7 |
| Q1 FY2026 | Mar 31, 2026 | -345.2% | +553.8 |
| Q4 FY2025 | Dec 31, 2025 | -121.8% | −5.9 |
| Q3 FY2025 | Sep 30, 2025 | -19.7% | −20.4 |
| Q2 FY2025 | Jun 30, 2025 | -581.0% | −50.3 |
| Q1 FY2025 | Mar 31, 2025 | -899.1% | −195.5 |
| Q4 FY2024 | Dec 31, 2024 | -115.9% | −123.7 |
| Q3 FY2024 | Sep 30, 2024 | 0.7% | +199.0 |
| Q2 FY2024 | Jun 30, 2024 | -530.7% | −129.5 |
| Q1 FY2024 | Mar 31, 2024 | -703.6% | −707.8 |
| Q4 FY2023 | Dec 31, 2023 | 7.7% | −21.1 |
| Q3 FY2023 | Sep 30, 2023 | -198.3% | −229.3 |
| Q2 FY2023 | Jun 30, 2023 | -401.2% | −447.4 |
| Q1 FY2023 | Mar 31, 2023 | 4.2% | −56.0 |
| Q4 FY2022 | Dec 31, 2022 | 28.8% | −38.7 |
| Q3 FY2022 | Sep 30, 2022 | 31.0% | −36.1 |
| Q2 FY2022 | Jun 30, 2022 | 46.3% | −17.6 |
| Q1 FY2022 | Mar 31, 2022 | 60.3% | −2.7 |
| Q4 FY2021 | Dec 31, 2021 | 67.5% | +115.3 |
| Q3 FY2021 | Sep 30, 2021 | 67.1% | +215.5 |
| Q2 FY2021 | Jun 30, 2021 | 63.8% | +238.5 |
| Q1 FY2021 | Mar 31, 2021 | 63.0% | +1613.0 |
| Q4 FY2020 | Dec 31, 2020 | -47.8% | +829.2 |
| Q3 FY2020 | Sep 30, 2020 | -148.4% | +574.4 |
| Q2 FY2020 | Jun 30, 2020 | -174.6% | +856.8 |
| Q1 FY2020 | Mar 31, 2020 | -1550.0% | −722.7 |
| Q4 FY2019 | Dec 31, 2019 | -877.0% | −477.8 |
| Q3 FY2019 | Sep 30, 2019 | -722.8% | −530.5 |
| Q2 FY2019 | Jun 30, 2019 | -1031.4% | −717.4 |
| Q1 FY2019 | Mar 31, 2019 | -827.3% | −578.1 |
| Q4 FY2018 | Dec 31, 2018 | -399.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -192.4% | – |
| Q2 FY2018 | Jun 30, 2018 | -314.0% | – |
| Q1 FY2018 | Mar 31, 2018 | -249.2% | – |
See a number that looks wrong?